Education
About Us
Working with TipRanks
Follow Us
Tectonic Therapeutic Inc (TECX)
NASDAQ:TECX
TECX Stock Chart & Stats
$19.99
-$0.66(-1.42%)
At close: 4:00 PM EST
$19.99
-$0.66(-1.42%)
Day’s Range― - ―
52-Week Range$13.70 - $56.00
Previous CloseN/A
Volume30.18K
Average Volume (3M)205.30K
Market Cap
$374.14M
Enterprise Value$106.94M
Total Cash (Recent Filing)$268.44M
Total Debt (Recent Filing)$1.24M
Price to Earnings (P/E)―
Beta1.56
Next Earnings
Mar 19, 2026EPS Estimate
-1.11Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.02
Shares Outstanding18,716,280
10 Day Avg. Volume202,508
30 Day Avg. Volume205,304
Financial Highlights & Ratios
PEG Ratio0.18
Price to Book (P/B)4.84
Price to Sales (P/S)0.00
P/FCF Ratio-11.51
Enterprise Value/Market Cap0.29
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda-1.64
Forecast
1Y Price Target
$81.25Price Target Upside306.45% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering6
EPS Forecast (FY)-4.83
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Early-stage Clinical SupportPositive Phase 1b datasets for TX45 reinforce an early efficacy signal in a selected patient population and support the rationale for continued clinical investment.
Financial RunwayA cash position sized to support operations into the fourth quarter of 2028 reduces near-term financing risk and helps sustain TX45 development plans.
Peer Trial AdvancementMerck's decision to move a similar program into Phase 3 establishes a clinical precedent that may boost confidence in the developmental pathway for Tectonic's TX45 and lift investor expectations.
Bears Say
Market Positioning RiskHigh short interest at over thirty percent of the float indicates sizable bearish positioning that could exacerbate share price declines if negative news emerges.
Program Clarity RiskAbsence of an update on AZD3427 creates uncertainty about that program's prospects and can act as an ongoing overhang on the stock until more information is provided.
Tectonic Therapeutic News
TECX FAQ
What was Tectonic Therapeutic Inc’s price range in the past 12 months?
Tectonic Therapeutic Inc lowest stock price was $13.70 and its highest was $56.00 in the past 12 months.
What is Tectonic Therapeutic Inc’s market cap?
Tectonic Therapeutic Inc’s market cap is $374.14M.
When is Tectonic Therapeutic Inc’s upcoming earnings report date?
Tectonic Therapeutic Inc’s upcoming earnings report date is Mar 19, 2026 which is in 45 days.
How were Tectonic Therapeutic Inc’s earnings last quarter?
Tectonic Therapeutic Inc released its earnings results on Nov 06, 2025. The company reported -$1.02 earnings per share for the quarter, beating the consensus estimate of -$1.056 by $0.036.
Is Tectonic Therapeutic Inc overvalued?
According to Wall Street analysts Tectonic Therapeutic Inc’s price is currently Undervalued.
Does Tectonic Therapeutic Inc pay dividends?
Tectonic Therapeutic Inc does not currently pay dividends.
What is Tectonic Therapeutic Inc’s EPS estimate?
Tectonic Therapeutic Inc’s EPS estimate is -1.11.
How many shares outstanding does Tectonic Therapeutic Inc have?
Tectonic Therapeutic Inc has 18,716,280 shares outstanding.
What happened to Tectonic Therapeutic Inc’s price movement after its last earnings report?
Tectonic Therapeutic Inc reported an EPS of -$1.02 in its last earnings report, beating expectations of -$1.056. Following the earnings report the stock price went up 1.738%.
Which hedge fund is a major shareholder of Tectonic Therapeutic Inc?
Currently, no hedge funds are holding shares in TECX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Tectonic Therapeutic Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$81.25 (306.45% Upside)
$81.25 (306.45% Upside)
Blogger Sentiment
Bullish
TECX Sentiment 70%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 334.7K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 2.1%
Last 30 Days ▼ 6.7%
Last 30 Days ▼ 6.7%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-63.54%
12-Months-Change
Fundamentals
Return on Equity
-32.21%
Trailing 12-Months
Asset Growth
64.18%
Trailing 12-Months
Company Description
Tectonic Therapeutic Inc
Tectonic Therapeutic, Inc., a clinical stage biotechnology company focuses on the discovery and development of therapeutic proteins and antibodies to modulate the activity of G-protein coupled receptors(GPCRs). It offers GEODe technology platform to enable the discovery and development of GPCR-targeted biologic medicines. The company's pipeline products include RXFP1 agonist, which is in ongoing phase 1a and 1b for the indication of heart failure with preserved ejection fraction; GPCR antagonist for indication of hereditary hemorrhagic telangiectasia; bi-functional GPCR modulator for indication of fibrosis; and GPCR modulators. Tectonic Therapeutic, Inc. is based in Watertown, Massachusetts.
TECX Stock 12 Month Forecast
Average Price Target
$81.25
▲(306.45% Upside)
Technical Analysis
Omeros
―
Abeona Therapeutics
―
Mereo Biopharma Group Plc
―
Foghorn Therapeutics
―
Lexeo Therapeutics, Inc.
―
Ownership Overview
38.61% Insiders
13.87% Mutual Funds
0.05% Other Institutional Investors
41.59% Public Companies and Individual Investors
Options Prices
Currently, No data available
---